vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $13.5M, roughly 1.4× UNITED SECURITY BANCSHARES). SCYNEXIS INC runs the higher net margin — 65.7% vs 25.2%, a 40.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 13.6%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 3.0%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
SCYX vs UBFO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $13.5M |
| Net Profit | $12.3M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 31.5% |
| Net Margin | 65.7% | 25.2% |
| Revenue YoY | 1808.5% | 13.6% |
| Net Profit YoY | 376.5% | 36.8% |
| EPS (diluted) | $0.25 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $13.5M | ||
| Q3 25 | $334.0K | $14.0M | ||
| Q2 25 | $1.4M | $12.6M | ||
| Q1 25 | $257.0K | $13.7M | ||
| Q4 24 | $977.0K | $11.9M | ||
| Q3 24 | $660.0K | $13.8M | ||
| Q2 24 | $736.0K | $13.0M | ||
| Q1 24 | $1.4M | $12.8M |
| Q4 25 | $12.3M | $3.4M | ||
| Q3 25 | $-8.6M | $4.0M | ||
| Q2 25 | $-6.9M | $2.2M | ||
| Q1 25 | $-5.4M | $2.7M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | $-2.8M | $3.8M | ||
| Q2 24 | $-14.5M | $4.3M | ||
| Q1 24 | $411.0K | $4.2M |
| Q4 25 | 56.3% | 31.5% | ||
| Q3 25 | -2516.5% | 40.3% | ||
| Q2 25 | -701.0% | 24.0% | ||
| Q1 25 | -3350.2% | 27.5% | ||
| Q4 24 | — | 27.5% | ||
| Q3 24 | -1563.6% | 37.1% | ||
| Q2 24 | -1255.0% | 46.4% | ||
| Q1 24 | -692.5% | 45.9% |
| Q4 25 | 65.7% | 25.2% | ||
| Q3 25 | -2572.2% | 28.7% | ||
| Q2 25 | -504.8% | 17.2% | ||
| Q1 25 | -2097.7% | 19.6% | ||
| Q4 24 | — | 20.9% | ||
| Q3 24 | -425.5% | 27.7% | ||
| Q2 24 | -1964.4% | 33.0% | ||
| Q1 24 | 29.9% | 32.6% |
| Q4 25 | $0.25 | $0.18 | ||
| Q3 25 | $-0.17 | $0.23 | ||
| Q2 25 | $-0.14 | $0.13 | ||
| Q1 25 | $-0.11 | $0.16 | ||
| Q4 24 | — | $0.14 | ||
| Q3 24 | $-0.06 | $0.22 | ||
| Q2 24 | $-0.30 | $0.25 | ||
| Q1 24 | $0.01 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $139.7M |
| Total Assets | $59.0M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $264.2M | ||
| Q3 25 | $37.9M | $211.1M | ||
| Q2 25 | $44.8M | $199.5M | ||
| Q1 25 | $40.6M | $198.4M | ||
| Q4 24 | $59.3M | $216.9M | ||
| Q3 24 | $68.8M | $216.8M | ||
| Q2 24 | $73.0M | $166.3M | ||
| Q1 24 | $80.2M | $168.6M |
| Q4 25 | $49.4M | $139.7M | ||
| Q3 25 | $36.4M | $137.4M | ||
| Q2 25 | $44.5M | $134.3M | ||
| Q1 25 | $50.5M | $132.9M | ||
| Q4 24 | $55.1M | $130.4M | ||
| Q3 24 | $58.5M | $132.9M | ||
| Q2 24 | $60.4M | $127.3M | ||
| Q1 24 | $74.1M | $124.2M |
| Q4 25 | $59.0M | $1.2B | ||
| Q3 25 | $51.1M | $1.2B | ||
| Q2 25 | $60.7M | $1.2B | ||
| Q1 25 | $67.9M | $1.2B | ||
| Q4 24 | $90.6M | $1.2B | ||
| Q3 24 | $99.0M | $1.3B | ||
| Q2 24 | $107.8M | $1.2B | ||
| Q1 24 | $118.3M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $22.1M |
| Free Cash FlowOCF − Capex | — | $19.8M |
| FCF MarginFCF / Revenue | — | 146.0% |
| Capex IntensityCapex / Revenue | — | 16.8% |
| Cash ConversionOCF / Net Profit | 1.50× | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $22.1M | ||
| Q3 25 | $-8.7M | $7.0M | ||
| Q2 25 | $-7.5M | $8.7M | ||
| Q1 25 | $-7.5M | $3.0M | ||
| Q4 24 | $-24.0M | $19.6M | ||
| Q3 24 | $765.0K | $5.4M | ||
| Q2 24 | $-10.9M | $2.3M | ||
| Q1 24 | $-4.0M | $7.4M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $18.6M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 64.3% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | — | 156.0% | ||
| Q3 24 | — | 38.1% | ||
| Q2 24 | — | 15.5% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 3.6% |
| Q4 25 | 1.50× | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | -9.75× | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
UBFO
Segment breakdown not available.
